Myeloma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been fully informed about the trial and have signed a consent form voluntarily.
• People aged 18 or older.
• People who have a confirmed diagnosis of Multiple Myeloma (a type of blood cancer affecting plasma cells).
• People whose Multiple Myeloma has returned or stopped responding to treatment, and who have soft-tissue tumours outside the bone (not growing from bone lesions) that are at least 2cm in size, confirmed by scans or biopsy, and who have had at least one prior round of treatment.
• People who are reasonably physically active and able to carry out basic daily tasks, as measured by a standard medical scoring system (confirm with trial site).
• People with no active infections at the time of joining.
• People who test negative for Hepatitis B virus, Hepatitis C virus, and HIV.
• People whose liver is functioning within acceptable levels based on specific blood test results (confirm with trial site).
• People whose kidneys are functioning at a sufficient level, based on a calculated measure of kidney filtering ability (confirm with trial site).
• People whose recent blood counts meet minimum required levels for white blood cells, haemoglobin, and platelets, tested within 7 days before screening (confirm with trial site).
• People who have stopped taking certain blood cell-stimulating medications (such as those that support red or white blood cell production) at least 2 weeks before screening.
• Women who are not pregnant, confirmed by a pregnancy test at the time of screening.
• Men, women of childbearing potential, and their partners who agree to use effective contraception during treatment and for at least 3 months after receiving the cell infusion.
• Men who agree not to donate sperm from the start of screening until 90 days after the last dose.
• People who agree to follow all study procedures and attend all required follow-up visits.

Who may not be able to join:

• People diagnosed with plasma cell leukaemia or a single isolated plasma cell tumour (solitary plasmacytoma).
• People who have previously received both BCMA-targeted and GPRC5D-targeted therapies (having received only one of these does not automatically exclude someone).
• People whose disease has shown resistance to elotuzumab, carfilzomib, or thalidomide.
• Women who are pregnant, breastfeeding, or planning to become pregnant within the next six months.
• People with active infectious diseases such as HIV or active tuberculosis.
• People with an active Hepatitis B or Hepatitis C infection.
• People with abnormal vital signs or who are unable to cooperate with medical examinations.
• People with mental health or psychological conditions that would prevent them from following the treatment plan or completing assessments.
• People with a history of severe allergic reactions, particularly to any of the medications used in this trial, including aponermin, carfilzomib, thalidomide, or dexamethasone.
• People with serious problems affecting major organs such as the heart, lungs, or brain.
• People with severe autoimmune diseases (conditions where the immune system attacks the body).
• People whom the trial doctors consider unsuitable for participation for any other medical reason.

Important: Always verify eligibility with the trial site directly before applying.